-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Zimmer Biomet delivered solid Q1 2026 results with net sales of $2.087B (+9.3% reported, +2.9% organic constant currency), $20M above the consensus view, and adjusted EPS of $2.09 (+15.5% Y/Y), beating the consensus by $0.23. Performance was broad-based across U.S. markets at $1.209B (+3.2% Y/Y organic) and international operations at $877.4M (+2.5% Y/Y organic). The diversified portfolio enabled resilient performance with knees at $828.6M (+1.8% organic), hips at $524.1M (+3.2% organic), and S.E.T. serving as a growth engine with sales at $562.2M, benefiting from the Paragon 28 acquisition. Management raised full-year EPS guidance to $8.40-$8.55 from $8.30-$8.45 while maintaining revenue guidance of 2.5%-4.5% reported growth. Key milestones in Q1 included mBos robotic system enrollment completion in India, first G7 Acetabular System case following FDA clearance, and Dr. Vigdorchik's appointment as Chief Science Officer.